Skip to main content

Genomic Solutions to Acquire GeneMachines for $8.3M

NEW YORK, March 3 - Genomic Solutions, a wholly owned subsidiary of Harvard Bioscience, said today that it plans to acquire genomic tool company GeneMachines for around $8.3 million in cash.

 

The acquisition is expected to close in mid March, subject to the approval of GeneMachines' shareholders. According to Harvard Bioscience, enough GeneMachines shareholders necessary to approve the transaction have already entered agreed to vote in favor of the acquisition.

 

GeneMachines develops and distributes high-throughput instrumentation for DNA and protein microarray production, nucleic acid sample preparation, and DNA synthesis.

 

Click here for further information.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.